Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 6/20 | 0.36 |
| ▸ | EDNRA | P25101 | 5/20 | 0.35 |
| ▸ | CCR4 | P51679 | 5/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376302 | 0.78 | IGF1R (0.39) | HCRTR2 | |
| SCHEMBL377034 | 0.78 | ALDH1A1 (0.34) | HCRTR2HCRTR1 | |
| SCHEMBL15203442 | 0.75 | EGFR (0.46) | — | |
| SCHEMBL3825299 | 0.75 | PIM2 (0.44) | — | |
| SCHEMBL14237447 | 0.75 | PIM2 (0.44) | — | |
| SCHEMBL2128328 | 0.73 | KMT2A (0.46) | HCRTR2HCRTR1 | |
| SCHEMBL3826467 | 0.72 | PIM1 (0.41) | — | |
| SCHEMBL17075698 | 0.72 | LDHA (0.37) | HCRTR2HCRTR1 | |
| SCHEMBL17536555 | 0.72 | HCRTR1 (0.39) | HCRTR2HCRTR1 | |
| SCHEMBL17536542 | 0.71 | DRD2 (0.42) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | HCRTR2 3784/4885EDNRA 4249/4885CCR4 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.